Alex Denner has made his first public move at The Medicines Company since consolidating power on the board — and it’s a big one.
Clive Meanwell passing the CEO role and his board seat to Merck vet Mark Timney, leaving a position he’s occupied for the better part of the company’s 22-year history.
He’s not out entirely. In the newly-created role of chief innovation officer, he is tasked with supporting the ongoing development of inclisiran — the biotech’s experimental LDL-lowering RNAi therapy in-licensed from Alnylam.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
Sign in to Endpoints News
I forgot my password
Request a magic link
Access is subject to the terms in our Privacy Policy.
Request a magic link
Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours. Access is subject to the terms in our Privacy Policy.
Set a new password
We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours. Access is subject to the terms in our Privacy Policy.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.
Free Subscription
LATEST
FEATURED
SIMILAR
Subscriber Comments
There are no comments so far. Add your own?